

The epidemiology and prevention of meningococcal disease in children

Stephen Hawkings

Hawkings S. The epidemiology and prevention of meningococcal disease in children. *J Pulmonol.* 2022; 6(3):34-36.

ABSTRACT

Neisseria meningitidis causes meningococcal illness; 13 serogroups have been found and distinguished from one another by their capsular polysaccharide. Nearly all infections in the globe are caused by serotypes A, B, C, W, X, and Y. Meningitis and invasive meningococcal illness are the most common clinical symptoms, both of which are associated with substantial mortality and long-term consequences. Children under the age of one year and adolescents, who are typically asymptomatic carriers, have a greater infection rate. The most efficient means of preventing infection and transmission is vaccination. Both monovalent (against A, B, and C serotypes) and quadrivalent (against serogroups ACYW) meningococcal vaccines are currently available and recommended based on local epidemiology. The goal of this article is to outline

meningococcal vaccinations and identify tools that can be used to reduce transmission and increase immunisation coverage. Switching from a monovalent to quadrivalent vaccine in the first year of life, increasing vaccine promotion against ACYW serotypes among adolescents, and extending the free anti-meningococcal B vaccine offer to teens, co-administering it with others proposed in the same age group could all help achieve this goal? Greater knowledge of the disease's seriousness, as well as greater health education via the internet and social media, may be the most effective strategy for increasing vaccination campaign adherence and active engagement. Finally, another key goal should be the development of a licenced universal meningococcal vaccination.

Key Words: *Invasive meningococcal disease; Children; Adolescents; Meningococcal vaccines; Immunization programmes*

INTRODUCTION

The bacteria *Neisseria meningitidis* (NM), a Gram-negative diplococcus, causes meningococcal illness, which is one of the meningitis in children [1]. Despite its rarity, meningococcal illness is a major public health concern in children, with an overall death rate of roughly 8% and potential neurological consequences [2]. This article focuses on the epidemiology of meningococcal disease and its prevention in children and adolescents by vaccination, with a focus on developed countries (Europe and North America) rather than low-income countries, particularly Africa.

Epidemiology

Capsular categories of NM have been discovered based on the polysaccharide capsule. Only six of them (A, B, C, W, X, and Y) are most commonly linked to human disorders [3]. The bacterium's only reservoir is humans, where it lives largely in the nasopharynx of asymptomatic people and can be spread to close contacts by respiratory droplets. Carriage rates are highest among teens and young adults, especially because their lifestyles involve

more personal contact, whereas newborns and elderly persons have lower carriage rates. Approximately 10% of people have a nasopharyngeal colonisation, When the pathogen reaches the bloodstream, it causes systemic illness, which can include meningitis, sepsis (meningococemia), or both. Meningococcal illness occurs at a rate of 0.11 to 1.5 cases per 100,000 people in the United States (US) per year [4]. 1.01 cases per 100,000 people in Europe. The distribution of the major capsular groups of NM that cause invasive illness currently varies greatly by geography. In most of Africa, serogroup W organisms predominate, accounting for 44–98% of infections [5]. Serogroup A is more common along the so-called "meningitis belt," which runs from Ethiopia to Senegal. Serogroups A and C are also responsible for significant outbreaks in Africa and Asia, but serogroups B and C are more prevalent in Europe and the Americas. Surprisingly, the incidence of meningococcal disease varies by age group, with a double peak distribution in the first years of life and teenagers and young adults [6]. In the United States, serogroup B causes 60 percent of meningococcal disease in newborns under the age of one year, whereas serogroup C, Y, and W cause 66 percent of cases in children older than 11 years.

Editorial Office, *Journal of Pulmonology, Singapore*

Correspondence: Stephen Hawkings, *Journal of Pulmonology, Singapore*, Telephone +65-461-4556876, E-mail: pulmonol@esciencejournals.org

Received: 04 March 2022, Manuscript No: PULJP-22-4648, Editor Assigned: 06-March-2022, PreQC No: PULJP-22-4648(PQ), Reviewed: 16-March-2022, QC No: PULJP-22-4648(Q); Revised: 18-March-2022; Manuscript No.: PULJP-22-4648(R); Published: 28 March 2022; DOI: 10.37532/pulj.22.6(3).34-36



This open-access article is distributed under the terms of the Creative Commons Attribution Non-Commercial License (CC BY-NC) (<http://creativecommons.org/licenses/by-nc/4.0/>), which permits reuse, distribution and reproduction of the article, provided that the original work is properly cited and the reuse is restricted to noncommercial purposes. For commercial reuse, contact reprints@pulsus.com

Hawkings

In a recent Italian survey, the incidence of invasive meningococcal illness increased from 0.25 cases per 100,000 in 2011 to 0.33 cases per 100,000 in 2017 [6]. Serogroup B was the most common in children under the age of five. In addition, cases of serogroups W and Y have increased over time.

Vaccines

Vaccines, including the polysaccharide capsule of single or multiple meningococcal serogroups, have been available for the past 40 years. These vaccines activate a B cell response, resulting in the creation of particular antibodies, but they do not stimulate long-term memory, resulting in lower antibody concentrations than those elicited by primary immunisation. Polysaccharide-conjugate vaccines were produced by conjugating the meningococcal polysaccharide antigen to protein carriers due to their ineffectiveness in terms of short-term protection, inability to generate immunological memory, and poor response to booster doses. Vaccine efficacy is determined in rich nations, where the incidence of meningococcal disease is low, by demonstrating particular immune responses, but in low-income countries, it is measured by an actual reduction in disease incidence. Functional antibodies against meningococcal antigens are measured using serum bactericidal antibody tests with human complement (hSBA) or baby rabbit complement (rSBA). The proportion of those who attain an SBA titer over a predetermined threshold or a fourfold increase in SBA titers for the studied serogroups is used to determine immunogenicity. The monovalent meningococcal conjugate vaccines In 1999, the Meningococcal C (MenC) conjugate vaccine was created. Actually, there are two MenC-CRMs (Meningitec, Nuron Biotech Inc., Exton, PA, USA and Menjugate, GlaxoSmithKline Biologicals SA, Rixensart, Belgium), both conjugated to diphtheria protein cross-reactive material 197, and one MenC-TT (NeisVac-C, Pfizer Inc., New York, NY, USA). The United Kingdom (UK) was the main country to permit the antibody for Meningococcus Serogroup C in the immunization plan, accomplishing an abatement of 86.7% in the frequency of serogroup C contamination in the designated age bunches from 1999 to 2001 and furthermore a decrease of 34-61%, contingent upon age, in the infection occurrence among unvaccinated youngsters. The MenC form antibodies are immunogenic as well as protected. At the hour of endorsement, in the UK, it was allowed from 2 months old enough in 3 dosages separated one month separated in the primary year of life. Many investigations showed that the adequacy declined by 81% soon. One more portion at a year old enough was found to initiate immunological memory and decline the quantity of transporters, with an ensuing decrease in the rate of the illness among the unvaccinated (group resistance). A solitary portion was suggested for get up to speed inoculation in youngsters 1 year and more established who were not recently immunized. Since July 2016, when levels of MenC disease were so low that children younger than 12 months of age were well protected by herd immunity, infants have received a single dose of a combination conjugate vaccine that includes Haemophilus influenzae type B (Hib/MenC vaccine Menitorix) at 12 months of age. The MenC vaccine is not used in the United States due to high rates of invasive meningococcal disease (IMD) caused by other serogroups in the Men ACWY vaccine. A single dose of the MenC vaccine is approved for children aged 13 to 15 months in Italy (with the option of three doses at 3, 5, and 11 months for children at increased risk of meningococcal disease); it is given in conjunction with other vaccines. The United Kingdom (UK) was the first country to include the meningococcus serogroup C vaccine in the vaccination schedule, resulting in an 86.7 percent reduction in serogroup C infection in the targeted age groups from 1999 to 2001, as well as a 34-61 percent reduction in disease incidence among unvaccinated children, depending on age [7]. Not only are the MenC conjugate vaccines immunogenic, but they are also safe. It was administered in three doses spaced one month apart throughout the first year of life

in the UK at the time of authorisation. Many studies have shown that after a year, the effectiveness drops by 81 percent. From July 2016, as the degrees of MenC infection were low to such an extent that youngsters more youthful than a year old enough were all around safeguarded by crowd resistance, babies have gotten a solitary portion of a mix form antibody that incorporates Haemophilus influenzae type B (Hib/MenC immunization Menitorix) at a year old enough. Because of the high rates of Invasive Meningococcal Disease (IMD) produced by other serogroups in the MenACWY vaccination, the MenC vaccine is not utilised in the United States. In Italy, a single dose of the MenC vaccine is approved between the ages of 13 and 15 months (with the option of three doses at 3, 5, and 11 months for children at increased risk of meningococcal disease); it is given in conjunction with the Measles, Mumps, Rubella, and Varicella Vaccines (MMRV). The World Health Organization (WHO) suggests the monovalent C meningococcal antibody for all babies at one year old enough as a feature of routine vaccination and for subjects who have had the meningococcal infection. Babies matured 2-11 months get 2 dosages at a 2-month span, trailed by a third portion around 1 year after the fact while kids more seasoned than a year old enough get a solitary portion. The presentation of the monovalent C meningococcal antibody in inoculation programs across Europe in 1999 brought about a fast decrease in the extent of MenC illness, trailed by a steady rate from 2013 to 2017. Among the joined 29 European Union nations revealing observation information, the pace of IMD cases declined from 1.9 to 1.1 cases per 100,000 populace somewhere in the range of 1999 and 2007. In 2017, of the 2979 IMDs with a distinguished serogroup that were accounted for to the European Centre for Disease Prevention and Control (ECDC), 16% were because of the C strain, dissipated particularly across focal and southern Europe. Beginning from 2011, serogroup B stays the fundamental driver of IMD among most European nations [8]. In the UK, the biggest pace of decline was seen in examinations directed after 2006, after the presentation of the meningococcal immunization, with a drop of 78-87% in MenC cases in babies <1 year old enough, 70-98% in subjects 1-4 years old, and 79-93% in subjects <18/20 years old. In Italy, beginning around 2013, immunization inclusion with the MenC antibody in something like two years of life has ascended from 77% to around 85%. In 2019, 189 instances of IMD were accounted for; in 2018 and 2017, 170 and 197 cases were enrolled, separately. In 2019, the occurrence of IMD was higher in babies <1 year (notice pace of 2.97 per 100,000) and in youngsters matured 1-4 years (warning rate 0.88 per 100,000). For age bunches in the reach from 0 to 4 years, MenC was liable for 15% of all cases, with MenB diseases beating the other serogroups. Though among youthful grown-ups matured 15-24 years, the warning rate stayed stable (0.58 per 100,000) from 2017 to 2019, with 31% of the affirmed cases due to serogroup C. As per epidemiological information on the frequency and predominance of IMD and on the situation with "nasopharyngeal transporter", consideration has been centered around the young adult populace, fully intent on persuading wellbeing specialists to execute a free MenB immunization program for this age bunch. Teenagers have the most noteworthy pace of colonization, being the primary repository and the significant wellspring of transmission of N. meningitis serogroup B. To be sure, asymptomatic meningococcal carriage is perceived as an age-subordinate peculiarity. The basic aims of a vaccine are first, individual protection against the specific disease, and second, disease prevention in both unimmunized and vaccinated people through a reduction in pharyngeal carriage and transmission (herd immunity, limiting the reservoir of the bacterium). Finally, by defining the appropriate vaccination method, a public health benefit in terms of cost-effectiveness is realised. While the initial goal of meningococcal vaccinations B has been successfully fulfilled through immunisation campaigns, CMenB has had no discernible effect on carriage prevalence.

Hawkings

-nce, resulting in a loss of herd protection. With respect to a review completed among January and March 2016 in Milan 5.3% of the populace matured 14-21 years were transporters (2560 in any case solid understudies were selected). Though, as exhibited in a review led in Genoa by which gathered 200 examples from February to May 2011, 18.5% of youths were transporters and serogroup B was the most well-known. In 2015-2016, there was a flare-up of IMD because of *N. meningitidis* serogroup C in Tuscany, Italy, after which a cross-sectional-overview was directed to evaluate the meningococcal carriage pervasiveness, which was 4.8% in general, with a pinnacle of 23.7% in 19 years of age. Serogroup B was the most pervasive (1.8%). In Italy, from 2011 to 2017, the level of IMD because of *N. meningitidis* B among adolescents (10-14 years) and youngsters (15-24 years) was 28% and 32%, separately; in 2018, it was 42.9% and 51.7% of the absolute announced cases, individually.

REFERENCES

1. Di Pietro GM, Biffi G, Castellazzi ML, et al. Meningococcal disease in pediatric age: a focus on epidemiology and prevention. *International J Env Res Public Health*. 2022;19(7):4035..
2. Thompson, MJ Ninis, N Perera R, et al. Clinical recognition of meningococcal disease in children and adolescents. *Lancet*. 2006;367:397-403.
3. Brady RC. Meningococcal infections in children and adolescents: update and prevention. *Adv Pediatr*. 2020;67:29-46.
4. Nadel S. Treatment of Meningococcal Disease. *J Adolesc Health*. 2016;59:21-28.
5. Pizza M, Bekkat-Berkani R, Rappuoli R. Vaccines against meningococcal diseases. *Microorganisms*. 2020;8(10):1521.
6. Borg J, Christie D, Coen PG, et al. Outcomes of meningococcal disease in adolescence: prospective, matched-cohort study. *Pediatrics*. 2009;123(3):502-509.
7. Buysse CM, Vermunt LC, Raat H, et al. Surviving meningococcal septic shock in childhood: long-term overall outcome and the effect on health-related quality of life. *Critical Care*. 2010;14(3):1-8.
8. Wang B, Afzali HH, Marshall H. The inpatient costs and hospital service use associated with invasive meningococcal disease in South Australian children. *Vaccine*. 2014;32(37):4791-8.